**8. References**


<sup>\*</sup> Corresponding Author


[3] Fodor JG, Frohlich JJ, Genest JJG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working group on Hypercholesterolemia

[4] Tierney LM, McPhee SJ, Papdakis MA. Current medical diagnosis and treatment. 43

[6] Statins for the prevention of cardiovascular events. National Institute for Health and

[9] Lithuanian Institute of Hygiene database. Reviewed 2012-04-09. Available:

[10] Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program

[11] Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J

[12] Braunwald E, Douglas P. Braunwald Heart Disease. A textbook of cardiovascular

[13] Anitschkow N. Über die Veranderungen der Kaninchenaorta bei experimenteller

[15] Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT)—importance

[16] European guidelines on cardiovascular disease prevention in clinical practice: executive

[17] Kuklina EV, Shaw KM, Hong Y. Vital Signs: Prevalence, Treatment, and Control of High Levels of Low-Density Lipoprotein Cholesterol — United States, 1999–2002 and

[18] Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowereing of LDL-cholesterol: a meta-analysis of data from 170,000

[19] Ballantyne C, ed. Clinical lipidology. A Companion to Braunwald's Heart Disease.

[20] LaRosa JC, Grundy SM, Waters DD, et al. Inten-sive lipid lowering with atorvastatin in

[21] Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target.

patients with stable coronary disease. N Engl J Med. 2005;352 (14):1425-1435.

[14] Kumar P, Clark M. Clinical medicine. Fifth edition. Saunders, 2002 p.1104-1107.

2005–2008. Morbidity & Mortality Weekly Report. 2011;60(4):109-114.

participants in 26 randomised trials. Lancet 2010; 376:1670–81.

and Other Dyslipidemias. CMAJ 2000;162(10):1441-7.

[5] OECD iLibrary. Health at a glance: Europe 2010. Available:

Clinical Excellence (NICE). January 2006. Available:

[7] National Health Council Annual Report 2010. Available: http://www3.lrs.lt/pls/inter/w5\_show?p\_r=697&p\_k=1

http://data.euro.who.int/hfadb/

http://www.hi.lt/news/391.html

Med. 2004;350(15):1495-1504.

medicine. The 6th edition. 2005 p.921-939.

summary. Eur Heart J 2007;28:2375-2414.

Philadelphia,PA. Saunders 2009, p.56 - 129.

JAMA 2007;298(7):786-798.

Cholesterinsteatose. Beitr Pathol Anat 1913;56:379-404.

then and now (reprinted). JAMA 2008 (300);11:1343-1345.

edition. Lange medical books/McGraw-Hill. 2004, p. 326-327.

http://ec.europa.eu/health/reports/docs/health\_glance\_en.pdf

http://www.nice.org.uk/nicemedia/pdf/TA094guidance.pdf

[8] European health for all database (HFA-DB). Reviewed 2012-04-09. Available:

Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.

